Following a recent review of Tussionex^® (hydrocodone polistirex and chlorpheniramine polistirex) – a cough syrup containing hydrocodone and chlorpheniramine– we determined the benefit-risk balance for the use of Tussionex^® to treat cough associated with cold or allergy in children was no longer favorable. Because of this, UCB proactively approached the U.S. Food and Drug Administration (FDA) to request that Tussionex^® be limited to use in adults.